



GLOBAL ACADEMY *of* WOMEN'S CANCER

**EUROPEAN
HYBRID MEETING**

Simply the Best Education
you can get

8/9 JULY
2022
MUNICH
GERMANY

PRELIMINARY PROGRAMME

(updated: 08/04/2022)

CONTENT

Welcome Message	1
Programme at a Glance	2–3
Programme Friday, July 8 th	4–6
Programme Saturday, July 9 th	7–10
Invited Faculty	11–12
Satellite Symposia Overview	13
Floor Plan	14
General Information	15–16
Sponsors	17

**The Global Academy of Women's Cancer – European Hybrid Meeting 2022
is supported by**



Berufsverband Niedergelassener und
ambulant tätiger Gynäkologischer Onkologen
in Deutschland e.V.



Dear Colleagues and Friends,

the 1st meeting of the Global Academy of Women's Cancer was held in Vienna on October 8–9, 2021.

We welcomed nearly 700 participants to the kick-off in person and virtually. The overall feedback from attendees was overwhelmingly positive, reinforcing our belief that the format was spot on in combining all women's cancers into one educational meeting. Therefore, second Global Academy event will be held on July 8–9, 2022 in Munich, Germany. Once again, we will hold the event as a hybrid format with 300 participants planned in Munich and another 600 participants online.

Keynote lectures, debates, speakers corner, meet the professor sessions, multidisciplinary panel discussions, case discussions and current issues will be presented. During the 1.5-day meeting in Munich, the latest results and treatment strategies will be summarized, discussed and presented by international experts.

The interactive congress offers a comprehensive overview of all new developments in breast and gynecological cancers, which account for 50% of all cancers in women, as well as direct exchange with the world's leading experts in these fields. The aim is to present the latest scientific findings in practical recommendations for everyday clinical practice.

We would like to invite you to actively participate in the event!

Join us and exchange ideas with your colleagues and experts from all over the world, broaden your knowledge and take away ideas and recommendations for your daily work.

We look forward to welcoming you in Munich!

Andreas du Bois, MD
Scientific Chair

Jonathan Ledermann, MD
Scientific Chair

Sherko Kümmel, MD
Scientific Chair

Peter Schmid, MD
Scientific Chair

Nadia Harbeck, MD
Local Scientific Chair

Sven Mahner, MD
Local Scientific Chair

Jalid Sehouli, MD
Local Scientific Chair

Marion Kiechle, MD
Local Scientific Chair

PROGRAMME AT A GLANCE

Friday, July 8th

Ballroom

Rumford

8:00		
9:00		
10:00		
11:00		
12:00	OPENING OF THE CONFERENCE	
	JOINT LECTURES I	
13:00	SATELLITE SYMPOSIUM I	
14:00	BREAK BRUNCH	
	JOINT LECTURES II	
15:00	BREAK	
16:00	BREAST CANCER SESSION 1	GYNAE-ONCOLOGY SESSION 1
17:00	BREAK	
18:00	SATELLITE SYMPOSIUM II	
	JOINT LECTURES III	
19:00		

PROGRAMME AT A GLANCE

Saturday, July 9th

Ballroom

Rumford

8:00		
9:00	BREAST CANCER SESSION 2	GYNAE-ONCOLOGY SESSION 2
10:00	BREAK	
11:00	SATELLITE SYMPOSIUM III	
12:00	SATELLITE SYMPOSIUM IV	
13:00	BREAK	
14:00	BREAST CANCER SESSION 3	GYNAE-ONCOLOGY SESSION 3
15:00	BREAK	
16:00	SATELLITE SYMPOSIUM V	
17:00	JOINT LECTURES IV	
18:00	CLOSING REMARKS AND FAREWELL	
19:00		

Friday, July 8th



12:00–12:05

OPENING OF THE CONFERENCE

12:05–13:00

Ballroom

JOINT LECTURES I

MY PERSONAL HIGHLIGHTS OF 2022

CHAIRS: ANDREAS DU BOIS, ESSEN, GERMANY

SHERKO KÜMMEL, ESSEN, GERMANY

12:05–12:20 ... in Breast Cancer (clinical)

Nadia Harbeck, Munich, Germany

12:20–12:35 ... in Breast Cancer (basic and translational)

Fabrice Andre, Villejuif, France

12:35–13:00 ... in Gynaecological Oncology

Barbara Schmalfeldt, Hamburg, Germany

13:00–14:00

Ballroom

SATELLITE SYMPOSIUM I

14:00–14:30

BREAK BRUNCH

14:30–15:30

Ballroom

JOINT LECTURES II

HEREDITARY BREAST AND GYNAE-CANCER/GENETICS

CHAIRS: ANTONIO GONZÁLEZ MARTIN, MADRID, SPAIN

SHANI PALUCH-SHIMON, JERUSALEM, ISRAEL

14:30–14:45 Hereditary Breast Cancer and BRCA: Risk assessment, genetic testing and clinical consequences

Shani Paluch-Shimon, Jerusalem, Israel

14:45–14:50 Discussion

14:50–15:05 Hereditary Ovarian and Breast Cancer: which Genes should be considered beyond BRCA 1+2

Marion Kiechle, Munich, Germany

15:05–15:10 Discussion

15:10–15:25 Prophylactic surgery in hereditary cancer syndromes

Nicoletta Colombo, Milan, Italy

15:25–15:30 Discussion

15:30–15:45

BREAK

Friday, July 8th

15:45–17:15

Rumford

GYNAE-ONCOLOGY SESSION 1

UTERINE CANCER

CASE DISCUSSIONS

CHAIRS: SVEN MAHNER, MUNICH, GERMANY
AMIT OZA, TORONTO, CANADA

15:45–16:00 Case 1: Second line treatment of endometrial cancer
Frederik Marmé, Mannheim, Germany

16:00–16:15 Discussion

16:15–16:30 Case 2: Incorporation of Immune Checkpoint Inhibitors
into cervical Cancer treatment
Nicoletta Colombo, Milan, Italy

16:30 – 16:45 Discussion

DEBATE

16:45–17:15 Will Immune checkpoint inhibitors replace
chemotherapy in frontline therapy of advanced
endometrial cancer?

16:45–16:55 Yes
Mansoor Raza Mirza, Copenhagen, Denmark

16:55–17:05 No, not yet
Christian Marth, Innsbruck, Austria

17:05–17:15 Discussion

Friday, July 8th



15:45–17:15

Ballroom

BREAST CANCER SESSION 1

»ADJUVANT THERAPY IN BREAST CANCER«

CHAIRS: REBECCA DENT, SINGAPORE

NADIA HARBECK, MUNICH, GERMANY

LECTURES

15:45–16:05 Adjuvant single agent endocrine therapy – how, when and for how long?

Michael Gnant, Vienna, Austria

16:05–16:25 Adjuvant CDK 4/6 inhibitors – ready for prime time?

Stephen Johnston, London, United Kingdom

16:25–16:45 Who needs adjuvant Chemotherapy in ER+ breast cancer?

Sherko Kuemmel, Essen, Germany

CASE DISCUSSION

16:45–17:00 Premenopausal ER+ Breast Cancer – Ovarian suppression, Fertility and Pregnancy

Alessandra Gennari, Novara, Italy

17:00–17:15 Discussion

17:15–17:45

BREAK

17:45–18:30

Ballroom

SATELLITE SYMPOSIUM II

18:30–19:30

Ballroom

JOINT LECTURES III

SUPPORTIVE CARE AND END STAGE DISEASE MANAGEMENT

CHAIRS: MARION KIECHLE, MUNICH, GERMANY

MICHAEL BRAUN, MUNICH, GERMANY

18:30–18:45 What do patients need and expect in late-stage disease

Jalid Sehouli, Berlin, Germany

18:45–19:00 Maintaining quality of life during treatment and in end stage disease

Florence Joly, Caen, France

19:00–19:15 AE-management, supportive care and end stage disease management

Rachel Würstlein, Munich, Germany

19:15–19:30 Discussion

19:30

GET TOGETHER

Saturday, July 9th

08:30–10:00

Rumford

GYNAE-ONCOLOGY SESSION 2

»SURGICAL ASPECTS IN GYNECOLOGICAL ONCOLOGY«

CASE DISCUSSIONS

CHAIRS: DAVID TAN, SINGAPORE

JALID SEHOULI, BERLIN, GERMANY

08:30–08:45 Case 3: Role of patient selection for cytoreductive surgery
in recurrent ovarian cancer

Andreas du Bois, Essen, Germany

08:45–09:00 Discussion

09:00–09:15 Case: 4: Management of bowel obstruction
in gynaecological oncology

Christina Fotopoulou, London, United Kingdom

09:15–09:30 Discussion

LECTURES

09:30–09:45 Update on the role of sentinel node surgery
in Gynaecological Cancers

David Cibula, Prague, Czech Republic

09:45–10:00 How to choose between neoadjuvant and primary surgery
upfront treatment of Ovarian Cancer

Sven Mahner, Munich, Germany

Saturday, July 9th



08:30–10:00
Ballroom

BREAST CANCER SESSION 2

»TREATMENT OF BREAST CANCER«

LECTURE

CHAIRS: NADIA HARBECK, MUNICH, GERMANY
OLEG GLUZ, MÖNCHENGLADBACH, GERMANY

08:30–08:50 Update on treatment of eTNBC
Peter Schmid, London, United Kingdom

DEBATE

08:50–09:20 Should we escalate or de-escalate depending on response to neoadjuvant chemo plus CIT in eTNBC?
Role of adjuvant CIT and/or treatment/combination with capecitabine/PARPi

08:50–09:00 Pro: **Rebecca Dent, Singapore**

09:00–09:10 Contra: **Javier Cortes, Madrid, Spain**

09:10–09:20 Discussion

LECTURE

09:20–09:40 Update on treatment of HER2+ EBC
Guiseppe Curigliano, Milan, Italy

DEBATE

09:40 –10:10 Can we escalate or de-escalate depending on response to neoadjuvant HER2-targeted therapy?
Role of shorter vs longer chemotherapy + HER2-blockade and/or adjuvant HER2-targeted therapy

09:40 –09:50 Pro: **Sara Tolaney, Boston, USA**

09:50 –10:00 Contra: **Carlos Barrios, Porto Alegre, Brazil**

10:00 –10:10 Discussion

10:00–10:15 BREAK

10:15–11:00 SATELLITE SYMPOSIUM III

11:00–11:45 SATELLITE SYMPOSIUM IV

11:45–12:15 BREAK LUNCH

Saturday, July 9th

12:15–14:00
Rumford

GYNAE-ONCOLOGY SESSION 3

»TREATMENT OF OVARIAN CANCER«

CASE DISCUSSION

CHAIRS: PHILIPP HARTER, ESSEN, GERMANY
CHRISTIAN MARTH, INNSBRUCK, AUSTRIA

12:15–12:30 Treatment of clear cell ovarian cancer
David Tan, Singapore

12:30–12:45 Discussion

DEBATE

12:45–13:30 Maintenance therapy of HR proficient ovarian cancer

12:45 - 13:00 Pro Bevacizumab:

Amit Oza, Toronto, Canada

13:00 - 13:15 Pro PARPi: **Philipp Harter, Essen, Germany**

13:15 - 13:30 Discussion

KEYNOTE LECTURES

13:30–13:45 Update on frontline therapy of advanced Ovarian Cancer
Jonathan Ledermann, London, United Kingdom

13:45–14:00 Update on second line therapy of Ovarian Cancer
Antonio Gonzales Martin, Madrid, Spain

12:15–14:00
Ballroom

BREAST CANCER SESSION 3

»METASTATIC BREAST CANCER«

CASE DISCUSSION

CHAIRS: JAVIER CORTES, MADRID, SPAIN
CARLOS BARRIOS, PORTO ALEGRE, BRAZIL

12:15–12:30 Optimal treatment sequences in ER-positive metastatic Breast Cancer

Hope Rugo, San Francisco, USA

12:30–12:35 Discussion

12:35–12:50 Oligometastatic and/or oligo-progressive disease
Carlos Barrios, Porto Alegre, Brazil

12:50–12:55 Discussion


LECTURES

12:55–13:10 Update on management of mTNBC
Peter Schmid, London, United Kingdom

13:10–13:25 Update on management of HER2+ MBC
Javier Cortes, Madrid, Spain

13:25–13:45 Update on management of ER+ MBC
Hope Rugo, San Francisco, USA

13:45–14:00 Discussion



PROGRAMME

Saturday, July 9th



14:00–14:30

BREAK

14:30–15:15

Ballroom

SATELLITE SYMPOSIUM V

15:15–16:45

Ballroom

JOINT LECTURES IV

»IMMUNO-ONCOLOGY AND PRECISION MEDICINE«

CHAIRS: JONATHAN LEDERMANN, LONDON, UNITED KINGDOM
GUISEPPE CURIGLIANO, MILAN, ITALY

15:15–15:30 Role of immunotherapy in breast cancer
Peter Schmid, London, United Kingdom

15:30–15:35 Discussion

13:35–15:50 Breast Cancer: Integrating molecular pathology and personalised medicine into routine daily patient treatment
Fabrice Andre, Villejuif, France

15:50–15:55 Discussion

15:55–16:10 Integrating molecular pathology and personalised medicine into routine daily patient treatment
Nicole Concin, Essen, Germany/Innsbruck, Austria

16:10–16:15 Discussion

16:15–16:30 HRD and beyond: new tests, new test strategies – what are the options 2022?
Isabelle Ray Coquard, Lyon, France

16:30–16:40 Discussion

16:45

CLOSING REMARKS AND FAREWELL

Fabrice Andre

Institut Gustave Roussy
114 rue Edouard Vaillant
94800 Villejuif, France
fabrice.andre@gustaverouss.fr

Carlos Barrios

Oncoclínicas Group
Oncology Research Center, São Lucas
Hospital, PUCRS
Latin American Cooperative Oncology
Group (LACOG)
Coroados 837
Porto Alegre RS 9190580 Brazil
barrios@tummi.org

Andreas du Bois

Evang.Kliniken Essen-Mitte
Huysens-Stiftung Essen-Huttrop
Klinik für Gynäkologie und
Gynäkologische Onkologie
Henricistr. 92
45136 Essen, Germany

Michael Braun

Rotkreuzklinikum
München
Frauenklinik
Taxisstraße 3
80637 Munich, Germany
michael.braun@swmbrk.de

David Cibula

Charles University and General
University Hospital
First Faculty of Medicine
LF UK Praha
Kateřinská 32
121 08 Prague 2

Nicoletta Colombo

Divisione di Ginecologia Oncologia
Medica
IRCCS Istituto Europeo di Oncologia
Via Ripamonti 435
20144 Milan, Italy
Nicoletta.colombo@ieo.it

Nicole Concin

Evang. Kliniken Essen-Mitte
Essen, Germany
University of Innsbruck
Innsbruck, Austria
n.concin@kem-med.com

Javier Cortes

Vall d'Hebron Institute of Oncology
Centro Cellex, Carrer de Natzalet,
115-117
08035 Barcelona, Spain
jacortes@vhio.net

Giuseppe Curigliano

University of Milan
Via Ripamonti, 435 - IEO - Istituto
Europeo di Oncologia
20141 MILAN, Italy
Giuseppe.Curigliano@unimi.it

Rebecca Dent

National Cancer Center Singapore
11 Hospital Cres
Singapore 169610
rebecca.dent@singhealth.com

Christina Fotopoulou

Imperial College London
Hammersmith Hospital
Du Cane Road, W12 7BH
London, UK
c.fotopoulou@imperial.ac.uk

Alessandra Gennari

Maggiore Hospital Novara
Corso Mazzini n. 18
28100 Novara, Italy
alessandra.gennari@med.uniupo.it

Michael Gnant

Medizinische Universität Wien
Brustgesundheitszentrum
Waehringer Guertel 18-20
1090 Vienna, Austria
michael.gnant@meduniwien.ac.at

Oleg Gluz

Brustzentrum Niederrhein
Ludwig-Weber-Straße 15
41061 Mönchengladbach, Germany
oleg.gluz@wsg-online.com

Antonio Gonzalez-Martin

Servicio de Oncologia Medica
Clinica Universidad de Navarra
Avenida P o XII, 36
31008 Madrid, Spain
aqonzalezma@unav.es

Nadia Harbeck

Frauenkliniken Großhadern und
Maistrasse-Innenstadt
Brustzentrum der Universität
München
Marchioninstr. 15
81377 Munich, Germany
nadia.harbeck@med.uni-muenchen.de

Philipp Harter

Evang.Kliniken Essen-Mitte
Huysens-Stiftung Essen-Huttrop
Klinik für Gynäkologie und
Gynäkologische Onkologie
Henricistr. 92
45136 Essen, Germany
gynaekologie@kem-med.com

Stephen Johnston

Royal Marsden NHS Foundation Trust
Royal Marsden Hospital-Sutton
Downs Rd.
Sutton SM2, 5PT, United Kingdom
Stephen.johnston@rmh.nhs.uk

Florence Joly

Centre de Lutte Contre le Cancer
(CLCC) de Normandie occidentale
Centre François Baclesse
3 Avenue du Général Harris - BP
45026
14076 CAEN CEDEX 5, Frankreich
f.joly@baclesse.unicancer.fr

Marion Kiechle

Technical University Munich
Ismaninger Str. 22
81675 Munich
marion.kiechle@tum.de

Sherko Kümmel

Evang.Kliniken Essen-Mitte
Huysens-Stiftung Essen-Huttrop
Klinik für Senologie/Brustzentrum
Henricistr. 92
45136 Essen, Germany
s.kuemmel@kliniken-essen-mitte.de

Jonathan Ledermann

Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road, London, W1T 4TJ
jonathan.ledermann@nhs.net

Sven Mahner

LMU Hospital
Clinic and Polyclinic for Obstetrics and Gynecology
Campus Großhadern and City Center – Maistrasse
Marchioninistr. 15
81377 Munich
Sven.Mahner@med.uni-muenchen.de

Frederik Marmé

University Medical Center Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
frederik.marme@umm.de

Christian Marth

Medizinische Universität Innsbruck
Universitätsklinik für Gynäkologie und Geburtshilfe
Anichstr. 35
6020 Innsbruck, Austria
christian.marth@i-med.ac.at

Amit Oza

Ontario Institute for Cancer Research
MaRS Centre
661 University Avenue, Suite 510
Toronto, Ontario Canada, M5G OA3
amit.oza@uhn.ca

Shani Paluch-Shimon

Hadassah University Hospital
Kiryat Hadassah
Jerusalem 91120, Israel

Isabelle Ray-Coquard

Léon Bérard Center – Department of Medical Oncology
Institute for Clinical Science
28 rue Laennec
69008 Lyon, France
isabelle.ray-coquard@lyon.unicancer.fr

Mansoor Raza Mirza

Nordic Society of Gynaecological Oncology
Dept. of Oncology
9431 Rigshospitalet
Copenhagen University Hospital
Blegdamsvej 9
2100 Copenhagen, Denmark
mansoor.raza.mirza@regionh.dk

Hope S. Rugo

University of California San Francisco
UCSF Helen Diller Family Comprehensive Cancer Center
1450 3rd St.
San Francisco, CA 94158

Barbara Schmalfeldt

UKE Hamburg
Martinstraße 52
20246 Hamburg
b.schmalfeldt@uke.de

Peter Schmid

Barts Cancer Institute
Charterhouse Square Campus
Charterhouse Square
London EC1M 5PZ, United Kingdom
p.schmid@qmul.ac.uk

Jalid Sehouli

Charité - University Medicine Berlin
Medical University of Berlin
Campus Virchow Clinic
Mittelallee 9 | Augustenburger Platz 1
13353 Berlin, Germany
jalid.sehouli@charite.de

David SP Tan

Cancer Science Institute (CSI)
14 Medical Dr,
#12-01 Centre for Translational Medicine
Singapore 117599
david_sp_tan@nuhs.edu.sg

Sara M. Tolaney

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215, USA
Sara_Tolaney@DFCI.HARVARD.EDU

Rachel Würstlein

LMU Hospital City Center
Breast Center
Maistraße 11, 80337 Munich
rachel.wuerstlein@med.uni-muenchen.de

Friday, July 8th

13:00–14:00 SATELLITE SYMPOSIUM I
Sanofi Genzyme

17:45–18:30 SATELLITE SYMPOSIUM II
AstraZeneca

Saturday, July 9th

10:15–11:00 SATELLITE SYMPOSIUM III
Gold Sponsor


11:00–11:45 SATELLITE SYMPOSIUM IV
Unconditional educational grant from Lilly Eli

14:30–15:15 SATELLITE SYMPOSIUM V
Gold Sponsor

FLOORPLAN

Room Plan

Ground Floor



CME Credits

An application will be made.

How to receive your CME Credits

To obtain CME credits, please fill in the evaluation form, which you will find in your congress map. To get your certificate of attendance with the CME credits, please return the evaluation form duly filled in to the registration desk.

Congress Date

July 8th–July 9th, 2022

Congress Organization



Gesellschaft für medizinische Projekte mbH



Project Manager:

Mrs. Beatrice Schröder

E-Mail: beatrice.schroeder@medconcept.org

Friedenstr. 58

15366 Neuenhagen bei Berlin, Germany

Phone: +49 (0)3342 42689-13

Fax: +49 (0)3342 42689-40

E-Mail: info@medconcept.org

Internet: www.medconcept.org

Congress Website

<http://www.global-academy-of-womens-cancer.org>

Congress Venue

HILTON MUNICH PARK

Am Tucherpark 7

80538 Munich, Germany

Phone: +49 (0)89 3845 0

Fax: +49 (0)89 3845 2588

E-Mail: info.munich@hilton.com

www.munich-park.hilton.com

Exhibition

A commercial exhibition will be held at the congress venue, close to the main meeting room.

Exhibition Opening Hours

Friday, July 8, 2022: 11:30–18:30

Saturday, July 9, 2022: 09:00–17:00

Insurance

The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect health and travel insurance.

Language and Translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

Registration and Information Desk

The registration desk is situated at the ground floor of the InterContinental Hotel to the right of the reception and in front of the meeting area entrance.

Registration Desk Opening Hours

Thursday, July 7, 2022 17:00–19:00 (early check-in)

Friday, July 8, 2022 10:00–19:00

Saturday, July 9, 2022 07:30–17:00

Platinum



Gold



Silver



Bronze

